• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Check-Cap Ltd. (Amendment)

    4/8/24 7:35:32 PM ET
    $CHEK
    Medical Electronics
    Health Care
    Get the next $CHEK alert in real time by email
    SC 13D/A 1 e663501_sc13da-checkcap.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D/A

    (Rule 13d-101)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

    § 240.13d-2(a)

     

    (Amendment No. 1)1

     

    Check-Cap Ltd.

    (Name of Issuer)

     

    Ordinary Shares, par value NIS 48.00

    (Title of Class of Securities)

     

    M2361E179

    (CUSIP Number)

     

    EQUITYLINE ALTERNATE ASSETS GP INC.

    550 Highway 7 East, 338

    Richmond Hill, Ontario L4B 3Z4

    416-999-3993

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    April 5, 2024

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.

     

    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7 for other parties to whom copies are to be sent.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

      

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

     

     

     

    CUSIP No. M2361E179

      

      1   NAME OF REPORTING PERSON  
             
           

    EquityLine Alternate Assets GP Inc. 

     
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            WC  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            CANADA  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         762,724  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              762,724  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            762,724  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            13.0%  
      14   TYPE OF REPORTING PERSON  
             
            CO  

     

     

     

     

    CUSIP No. M2361E179

      

      1   NAME OF REPORTING PERSON  
             
           

    Sergiy Shchavyelyev 

     
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            OO  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            CANADA  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         762,724  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              762,724  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            762,724  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            13.0%  
      14   TYPE OF REPORTING PERSON  
             
            IN  

     

     

     

     

    CUSIP No. M2361E179

     

     

    Explanatory Note

     

    This Amendment No. 1 to Schedule 13D (“Amendment No. 1”) amends and supplements the statement on Schedule 13D filed by the Reporting Persons with the Securities and Exchange Commission (the “Commission”) on April 1, 2024 (the “Original Schedule 13D”), relating to the Ordinary Shares, par value NIS 48.00 (the “Shares”) of Check-Cap Ltd., an Israeli corporation (“Check-Cap” or the “Company”). Except to the extent set forth in this Amendment No. 1, all material information disclosed in the Original Schedule 13D remains unchanged. Capitalized terms used but not defined in this Amendment No. 1 have the respective meanings set forth in the Original Schedule 13D.

     

    In Item 4 of the Original Schedule 13D, the Reporting Persons expressed concern about the state of affairs of the Company, including the Company’s announcement of its entry into a business combination agreement, dated as of March 25, 2024, with Nobul AI Corp. (“Nobul”). The Reporting Persons hereby retract and disclaim the statements and concerns previously made in Item 4 of the Original Schedule 13D.

     

    The Reporting Persons now believe the Company’s recent leadership changes to management and refreshment of the Company’s Board of Directors will help the Company achieve its goals and are in the best interests of the Company’s shareholders. In addition, the Reporting Persons now understand that the control issues relating to the resignation of the Company’s former auditor have now been resolved. Finally, after conducting their own diligence, the Reporting Persons are excited by the Company’s potential business combination with Nobul and believe it to be in the best interests of the Company’s shareholders.

     

      Item 4. Purpose of Transaction.

     

    Item 4 of Schedule 13D is hereby amended and restated as follows:

     

    The Reporting Persons have no plans or proposals relating to or which would result in any of the matters set forth in clauses (a) through (j) of Item 4 of Schedule 13D.

     

      Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

     

    Item 6 of Schedule 13D is hereby amended and restated as follows:

     

    On April 5, 2024, EquityLine Alternate Assets GP Inc., a corporation incorporated under the laws of the Province of Ontario, Canada, Sergiy Shchavyelyev, the sole director of EquityLine, and each of the other Check-Cap shareholders (each, a “Shareholder” and, collectively, the “Shareholders”) signatory to the Support Agreement (as defined below), and Check-Cap Ltd., an Israeli company (“Check-Cap” or the “Company”), entered into a support agreement (the “Support Agreement”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Support Agreement.

     

    Pursuant to the Support Agreement, each Shareholder irrevocably and unconditionally agreed to vote at (i) the Check Cap Shareholder Meeting (or any adjournment or postponement thereof); (ii) at the April EGM (or any adjournment or postponement thereof); and (iii) at any other meeting of the shareholders of Check-Cap to the extent in respect of, or related to, the transactions contemplated under the BCA, all of the Shares held by such Shareholder at such time (a) in favor of the approval and adoption of the Check-Cap Shareholder Transaction Matters; (b) against any Acquisition Proposal or any of the transactions contemplated thereby, (c) against any other action that would reasonably be expected to materially impede, interfere with, delay, postpone or adversely affect the Check-Cap Shareholder Transaction Matters or result in a breach of any covenant representation or warranty or other obligation or agreement of Check-Cap under the BCA; and (d) in favor of all items on the agenda of the April EGM, as may be amended.

     

     

     

     

    CUSIP No. M2361E179

     

     

    Pursuant to the Support Agreement, each Shareholder agreed that it shall not, directly or indirectly, (a) sell, assign, transfer (including by operation of Law or by terminating the Coordination Agreement), pledge, dispose of or otherwise encumber any of the Shares or otherwise agree to do any of the foregoing, except for a sale, assignment or transfer pursuant to the BCA, (b) deposit any Shares into a voting trust or enter into a voting agreement or arrangement or grant any proxy or power of attorney with respect thereto that is inconsistent with the Support Agreement or (c) enter into any contract, option or other arrangement or undertaking with respect to the direct or indirect acquisition or sale, assignment, transfer (including by operation of Law) or other disposition of any Shares.

     

    Under the terms of the Support Agreement, the Shareholders agreed to certain standstill provisions, for the duration of the Standstill Period. The standstill provisions generally prohibit the Shareholders from taking specified actions during the Standstill Period with respect to the Company and its securities, including, among others: (i) soliciting or participating in the solicitation of proxies; (ii) joining any other “group” or becoming party to any agreement regarding any securities of the Company; (iii) seeking or encouraging others to submit nominations for the election or removal of directors; (iv) making shareholder proposals at any annual or extraordinary general meeting of shareholders or offers with respect to mergers, acquisitions and other business combinations; or (v) calling, or supporting another shareholder’s call of, an extraordinary general meeting of shareholders.

     

    The foregoing description does not purport to be complete and is qualified in its entirety by reference to the full text of the Support Agreement, a copy of which is attached as an exhibit hereto and is incorporated herein by reference.

     

      Item 7. Material to be Filed as Exhibits.
         
      99.1 Support Agreement by and among EquityLine Alternate Assets GP Inc., Sergiy Shchavyelyev, each of the other Check-Cap shareholders signatory to the Support Agreement, and Check-Cap Ltd.

     

     

     

     

    CUSIP No. M2361E179

      

     

    SIGNATURES

     

    After reasonable inquiry and to the best of his knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: April 8, 2024

     

      EquityLine Alternate Assets GP Inc.
       
      By:

    /s/ Sergiy Shchavyelyev

        Name: Sergiy Shchavyelyev
        Title: Sole Director

     

     

    /s/ Sergiy Shchavyelyev

      Sergiy Shchavyelyev

     

     

     

     

     

     

     

     

     

     

    Get the next $CHEK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CHEK

    DatePrice TargetRatingAnalyst
    8/9/2021$4.00 → $3.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CHEK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Apollo Technology Capital Corporation to Nominate Six Highly Qualified Directors to MediPharm Labs' Board of Directors Following Years of Shareholder Value Destruction

      Believes Board Change is Urgently Needed: Under the Current Board and Management, MediPharm Stock Price is Down More Than 99%, Costing Shareholders Nearly $1 Billion MediPharm's Board Cannot be Trusted to Create Shareholder Value or Oversee Management! Company Leadership Lacks Any Credible Strategic Plan and Has Made Numerous Reckless Acquisitions While Rewarding Themselves with Excessive Compensation for Repeated Failures Apollo's Nominees Bring Significant Turnaround, M&A, and Operational Experience in Cannabis and Adjacent Industries, and Will Execute Plan to Restore Value for ALL MediPharm Shareholders Urges MediPharm Shareholders to Vote for Wholesale Change at Annual Meeting Sends Le

      5/9/25 2:08:00 PM ET
      $CHEK
      Medical Electronics
      Health Care
    • Apollo Technology Capital Corporation to Nominate Six Highly Qualified Directors to MediPharm Labs' Board of Directors Following Years of Shareholder Value Destruction

      Believes Board Change is Urgently Needed: Under the Current Board and Management, MediPharm Stock Price is Down More Than 99%, Costing Shareholders Nearly $1 Billion MediPharm's Board Cannot be Trusted to Create Shareholder Value or Oversee Management! Company Leadership Lacks Any Credible Strategic Plan and Has Made Numerous Reckless Acquisitions While Rewarding Themselves with Excessive Compensation for Repeated Failures Apollo's Nominees Bring Significant Turnaround, M&A, and Operational Experience in Cannabis and Adjacent Industries, and Will Execute Plan to Restore Value for ALL MediPharm Shareholders Urges MediPharm Shareholders to Vote for Wholesale Change at Annual Meeting Sends Let

      5/8/25 7:30:00 AM ET
      $CHEK
      Medical Electronics
      Health Care
    • Nobul AI Corp and Check-Cap Ltd Enter into Definitive Business Combination Agreement

      Proposed business combination to create a North American technology company with an AI-driven fintech marketplace. Combined company to apply for listing on Nasdaq and TSX TORONTO, March 25, 2024 /PRNewswire/ -- Nobul AI Corp. ("Nobul") and Check-Cap Ltd. ("Check-Cap" or the "Company") (NASDAQ:CHEK) today announced that they have entered into a definitive Business Combination Agreement (the "Business Combination Agreement") under which the shareholders of Nobul will become the majority holders of the combined company. If completed, the business combination will create a public company headquartered in Toronto, Canada and focused on an AI-driven fintech marketplace as well as buying and AI-ena

      3/25/24 7:15:00 PM ET
      $CHEK
      Medical Electronics
      Health Care

    $CHEK
    SEC Filings

    See more
    • SEC Form NT 20-F filed by Check-Cap Ltd.

      NT 20-F - Check-Cap Ltd (0001610590) (Filer)

      5/1/25 4:15:02 PM ET
      $CHEK
      Medical Electronics
      Health Care
    • SEC Form 6-K filed by Check-Cap Ltd.

      6-K - Check-Cap Ltd (0001610590) (Filer)

      4/15/25 4:15:15 PM ET
      $CHEK
      Medical Electronics
      Health Care
    • SEC Form 6-K filed by Check-Cap Ltd.

      6-K - Check-Cap Ltd (0001610590) (Filer)

      12/31/24 4:15:09 PM ET
      $CHEK
      Medical Electronics
      Health Care

    $CHEK
    Leadership Updates

    Live Leadership Updates

    See more
    • Symetryx Today Issues Open Letter to Shareholders In Regard to the Upcoming Annual General Meeting

      Recommends Fellow Shareholders Vote AGAINST Keystone Transaction & the Check-Cap Board Nominees - Further Recommends a Vote FOR the Symetryx Slate of Director Candidates Cites Unrealistic and Aggressive Valuation of Keystone Used to Justify the Merger and Troubling Cash Burn by Check-Cap Board & Management TORONTO, Nov. 28, 2023 /PRNewswire/ - Symetryx, a holder of 5.6% of Check-Cap Ltd. (NASDAQ:CHEK) shares, today issued the following open letter to shareholders. In the letter Symetryx cites, among other items, its serious concerns and reason for voting AGAINST the proposed transaction with Keystone Dental.  Symetryx discusses its concerns around the actions of the Board in its evaluation

      11/28/23 11:56:00 AM ET
      $CHEK
      Medical Electronics
      Health Care
    • Check-Cap Appoints Dr. Hanit Brenner-Lavie as Vice President of Clinical Affairs

      ISFIYA, Israel, Sept. 1, 2021 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ:CHEK), (NASDAQ:CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced the appointment of Dr. Hanit Brenner-Lavie as Vice President of Clinical Affairs. Dr. Brenner-Lavie will be responsible for leading the Company's overall clinical strategy and implementation as well as driving the Company's clinical direction, including innovation. "Dr. Brenner-Lavie has a proven track record of clinical strategy dev

      9/1/21 8:30:00 AM ET
      $CHEK
      Medical Electronics
      Health Care

    $CHEK
    Financials

    Live finance-specific insights

    See more
    • Keystone Dental Group Granted Patent from USPTO for Nexus IOS Solution

      IRVINE, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Osteon Medical, a subsidiary of Keystone Dental Holdings ("Keystone Dental" or the "Company"), today announced the United States Patent and Trademark Office (USPTO) has granted the Company a patent for its innovative Nexus IOS solution. The Nexus iOS Scan Gauge technology allows implant dentists to perform direct full-arch implant scans using an Intraoral Scanner (IOS) with predictable and passive fitting prosthetic outcomes. This technology replaces the traditionally manual impression-taking process through a faster, cost-effective, and accessible workflow. The Nexus iOS Scan Gauge technology is now the only patented elongated body scan

      10/18/23 4:05:00 PM ET
      $CHEK
      Medical Electronics
      Health Care
    • Keystone Dental Holdings and Check-Cap Ltd Enter into Definitive Business Combination Agreement

      Proposed business combination to create a Nasdaq-listed medical device company focused on advancing the commercial execution and market development of Keystone's comprehensive portfolio of implants, arches and other tooth replacement solutions Keystone 2022 revenues exceeded $60 million The combined company will trade on the NASDAQ with the ticker "KSD" Investor conference call and webcast scheduled for 8:30 a.m. ET on Thursday, August 17th IRVINE, Calif. and BURLINGTON, Mass., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Keystone Dental Holdings, Inc. ("Keystone Dental") and Check-Cap Ltd. ("Check-Cap" or the "Company") (NASDAQ:CHEK) today announced that they have entered into a definitive Busin

      8/16/23 5:08:47 PM ET
      $CHEK
      Medical Electronics
      Health Care

    $CHEK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Check-Cap Ltd. (Amendment)

      SC 13D/A - Check-Cap Ltd (0001610590) (Subject)

      4/8/24 7:35:32 PM ET
      $CHEK
      Medical Electronics
      Health Care
    • SEC Form SC 13D filed by Check-Cap Ltd.

      SC 13D - Check-Cap Ltd (0001610590) (Subject)

      4/1/24 9:26:38 PM ET
      $CHEK
      Medical Electronics
      Health Care
    • SEC Form SC 13D/A filed by Check-Cap Ltd. (Amendment)

      SC 13D/A - Check-Cap Ltd (0001610590) (Subject)

      12/18/23 6:07:13 AM ET
      $CHEK
      Medical Electronics
      Health Care

    $CHEK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Check-Cap with a new price target

      HC Wainwright & Co. reiterated coverage of Check-Cap with a rating of Buy and set a new price target of $3.00 from $4.00 previously

      8/9/21 6:35:25 AM ET
      $CHEK
      Medical Electronics
      Health Care
    • Check-Cap downgraded by Dawson James with a new price target

      Dawson James downgraded Check-Cap from Buy to Neutral and set a new price target of $2.00

      3/17/21 12:12:30 PM ET
      $CHEK
      Medical Electronics
      Health Care
    • HC Wainwright & Co. reiterated coverage on Check-Cap with a new price target

      HC Wainwright & Co. reiterated coverage of Check-Cap with a rating of Buy and set a new price target of $4.00 from $1.50 previously

      3/16/21 6:31:50 AM ET
      $CHEK
      Medical Electronics
      Health Care